BioNTech (NASDAQ:BNTX) Shares Up 7.4% – Here’s What Happened

BioNTech SE Sponsored ADR (NASDAQ:BNTX) was up 7.4% on Friday . The stock traded as high as $120.33 and last traded at $119.05. 1,254,472 shares were traded during trading, an increase of 16% from the average session volume of 1,084,099 shares. The stock had previously closed at $110.89.

More BioNTech News

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: BioNTech shares increased alongside Moderna as the mRNA trade rebounded for a third session. The move reflects renewed investor interest in mRNA-based cancer vaccines after Moderna’s trial news, rather than a new BioNTech announcement. Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session
• Positive Sentiment: BioNTech highlighted upcoming late-stage lung-cancer data at the 2026 World Conference on Lung Cancer, including first global data for the pumitamig/elfetabart drozuntecan combination. The planned presentations support the company’s pipeline narrative and could provide future catalysts, although the data are not yet available. BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data
• Neutral Sentiment: BioNTech became the focus of unusually high options activity, indicating elevated speculative positioning and expectations for continued volatility. Options volume alone does not establish the direction of the stock. BioNTech Target of Unusually High Options Trading
• Negative Sentiment: The stock previously pulled back as Moderna gave back part of its sharp cancer-vaccine rally, demonstrating that BNTX remains highly sensitive to peer-company data and shifting mRNA-sector sentiment. Analysts also cautioned that the rally driven by Moderna’s results may fade without BioNTech-specific evidence. BioNTech’s Rally on Moderna Trial Win Likely to Fade

Wall Street Analysts Forecast Growth

BNTX has been the subject of several recent analyst reports. Berenberg Bank decreased their target price on BioNTech from $155.00 to $140.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. Canaccord Genuity Group set a $142.00 price target on BioNTech in a research report on Wednesday, August 5th. Morgan Stanley reduced their price objective on BioNTech from $126.00 to $119.00 and set an “overweight” rating for the company in a research note on Wednesday, July 8th. Wall Street Zen downgraded shares of BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $127.81.

BioNTech Trading Up 4.6%

The stock has a market capitalization of $29.32 billion, a price-to-earnings ratio of -14.81 and a beta of 1.27. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average of $92.91 and a two-hundred day moving average of $95.64.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. During the same quarter last year, the business earned ($1.60) EPS. The company’s revenue for the quarter was down 59.5% on a year-over-year basis. On average, research analysts expect that BioNTech SE Sponsored ADR will post -6.33 EPS for the current year.

BioNTech announced that its Board of Directors has initiated a stock buyback plan on Thursday, May 7th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 4.2% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s board believes its stock is undervalued.

Institutional Investors Weigh In On BioNTech

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Nykredit A S acquired a new stake in BioNTech during the second quarter worth $293,000. B. Metzler seel. Sohn & Co. AG increased its holdings in shares of BioNTech by 66.7% in the second quarter. B. Metzler seel. Sohn & Co. AG now owns 10,967 shares of the company’s stock valued at $1,020,000 after purchasing an additional 4,390 shares in the last quarter. Headlands Technologies LLC bought a new stake in BioNTech during the 2nd quarter worth about $2,520,000. Flossbach Von Storch SE bought a new stake in shares of BioNTech during the second quarter worth approximately $207,142,000. Finally, PensionDanmark Pensionsforsikringsaktieselskab raised its position in shares of BioNTech by 10.9% during the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 8,290 shares of the company’s stock valued at $771,000 after acquiring an additional 816 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.